In order to further examined the impact of USP36 on the ER positive breast cancer phenotype, by overexpressing of USP36 wild-type (WT) plasmid, and USP36 catalytically inactive mutant (C131A) [19], We found that USP36 WT and USP36 C131A was successfully achieved, as validated by western blotting (Fig. 3A-B). The gene discussed is USP36; the disease is breast cancer.